文献速递静脉血栓栓塞慢性静脉疾病

GLP-1受体激动剂与肥胖慢性静脉功能不全患者静脉血栓事件及肢体并发症减少相关

Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-06-20

本研究为回顾性多中心队列研究,利用TriNetX数据库纳入138853例肥胖合并慢性静脉功能不全(CVI)的成年患者,其中12874例(9.3%)接受GLP-1治疗,经倾向评分匹配后每组12379例。结果显示GLP-1治疗与1年及3年急性深静脉血栓、肺栓塞、静脉性溃疡和软组织感染风险降低相关,并伴有绝对生存获益。

要点

  • 肥胖CVI患者使用GLP-1与1年急性DVT风险降低相关(HR 0.54)。
  • GLP-1治疗与1年及3年PE、静脉溃疡和软组织感染风险降低持续相关。
  • GLP-1治疗组1年绝对生存获益4%,3年绝对生存获益9%。

核心结论

  • 在肥胖CVI患者中,GLP-1治疗与静脉血栓栓塞事件、静脉性溃疡和软组织感染风险降低及长期生存改善相关。
  • GLP-1使用可能对CVI患者具有临床保护作用,但需未来研究进一步明确其在静脉疾病管理中的作用。

研究设计与样本

  • 回顾性多中心队列研究,使用TriNetX美国协作网络数据库。
  • 纳入2016至2025年间年龄≥40岁、BMI≥30 kg/m2且诊断为CVI的成年患者。
  • 共纳入138853例肥胖CVI患者,其中12874例(9.3%)接受GLP-1治疗。
  • 经倾向评分1:1匹配后,GLP-1组与非GLP-1组各12379例;匹配变量包括年龄、种族、性别、吸烟史、糖尿病、BMI、药物及其他合并症。
  • 排除有DVT和PE既往史的患者;主要结局为CVI诊断后1年和3年急性DVT风险。

主要发现

  • 倾向评分匹配后,1年时GLP-1治疗与急性DVT风险降低相关(HR 0.54;95%CI 0.42-0.71;P<.001)。
  • 1年时GLP-1治疗与PE风险降低相关(HR 0.43;95%CI 0.27-0.66;P<.001)。
  • 1年时GLP-1治疗与静脉性溃疡风险降低相关(HR 0.47;95%CI 0.33-0.66;P<.001)。
  • 1年时GLP-1治疗与软组织感染风险降低相关(HR 0.61;95%CI 0.52-0.72;P<.001)。
  • GLP-1治疗与DVT、PE、静脉性溃疡和软组织感染风险降低的关联在3年随访时持续存在。

临床怎么用

  • 对于肥胖合并CVI的患者,GLP-1治疗可能与静脉血栓栓塞事件及肢体并发症风险降低相关,可考虑作为综合管理的一部分。
  • 需结合患者个体情况评估GLP-1治疗的获益与风险,并进一步前瞻性研究验证。

局限性

  • 本研究为回顾性队列研究,可能存在残余混杂和选择偏倚。
  • 结论基于TriNetX数据库分析,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite the well-documented impact of glucagon-like peptide-1 receptor agonist (GLP-1) therapy on obesity and diabetes, and the known risk factors for chronic venous insufficiency, the relationship between GLP-1 use and venous disease outcomes remains poorly understood. This study aims to assess the association between GLP-1 therapy and the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), venous leg ulcers, cellulitis, and all-cause mortality at 1 year and 3 years following diagnosis in obese patients with chronic venous insufficiency (CVI). METHODS: We conducted a retrospective multicenter cohort study using the TriNetX US Collaborative Network to identify adult patients (≥40 years) who were obese (body mass index ≥30 kg/m2) and had a diagnosis of CVI between 2016 and 2025. Patients who were started on GLP-1 therapy were matched 1:1 to a non-GLP-1 cohort using propensity scores that accounted for age, race, sex, smoking history, diabetes, body mass index, medications, and other comorbidities. Covariate balance was assessed using standardized mean differences, with values <0.1 indicating adequate balance. Patients with CVI and a prior history of DVT and PE were excluded from the study. The primary outcome was acute DVT risk at 1-year and 3-year follow-up after a CVI diagnosis. Secondary outcomes included PE, venous ulcers, associated soft-tissue infections, and all-cause mortality at both time points. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for our outcomes. Time-to-event analyses were assessed using Kaplan-Meier survival curves, with intercohort comparisons performed using the log-rank test. Statistical significance was set at a two-sided α of .05. All analyses were conducted within the TriNetX Analytics platform. RESULTS: Of the 138,853 obese patients with CVI included in our study, 12,874 patients (9.3%) were treated with GLP-1s. After propensity score matching, each cohort consisted of 12,379 patients with CVI and obesity. Following propensity score matching, GLP-1 therapy was associated with a decreased risk of acute DVT (HR, 0.54; 95% CI, 0.42-0.71; P < .001), PE (HR, 0.43; 95% CI, 0.27-0.66; P < .001), venous ulcers (HR, 0.47; 95% CI, 0.33-0.66; P < .001), and soft-tissue infections (HR, 0.61; 95% CI, 0.52-0.72; P < .001) at 1 year in patients with CVI and obesity. The association between GLP-1 therapy and reduced risk of developing DVT, PE, venous ulcers, and soft-tissue infections was sustained at the 3-year follow-up. At both 1- and 3-year follow-up, patients with treated with GLP-1 demonstrated a 4% (99.0% vs 94.0%; P < .001) and 9% (95.0% vs 86.0%; P < .001) absolute survival benefit, respectively, compared with their non-GLP-1 counterparts. CONCLUSIONS: In obese patients with CVI, GLP-1 therapy was associated with reduced risk of venous thromboembolic events, venous leg ulcers, and soft-tissue infections, as well as improved long-term survival. These findings suggest that GLP-1 use may confer clinically protective effects in patients with CVI. Future studies are warranted to better understand the role of GLP-1 treatment in the management of venous disease.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Micalo L, Archie M, Rowe VL, et al. Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42323127. doi:10.1016/j.jvsv.2026.102557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。